Vivakor Presents at Nutraceutical Event

CORALVILLE, Iowa, Nov. 12 /PRNewswire-FirstCall/ -- Vivakor, Inc. (OTC
Bulletin Board: VIVK) is the keynote presenting company at the founders'
celebration of consumer product specialist, Regeneca International, Inc.
(www.regeneca.com). The celebration will be attended by over 200 founders and
guests of Regeneca International from across the United States. It will be
hosted at the prestigious Balboa Bay Club in Newport Beach, California.
Vivakor's Chairman, Matt Nicosia and CFO, Ed Corrente will both be attending
the event.

Event attendee, Dr. Brian Scott , a Regeneca advisory board member and
nationally recognized wellness expert, was particularly pleased to learn of
Vivakor's role in the event. "As a healthcare provider and speaker on issues
regarding wellness and longevity, it is refreshing to hear the perspective of
a company, doing business internationally, which can provide a particular
focus on products which extend the length and quality of a person's life."

The purpose of the event is to introduce Regeneca's new product offerings that
are to be released in the coming months, most significantly, the new
nutraceutical formulation developed by Vivakor."

About Vivakor, Inc.

Vivakor, Inc. is a transdisciplinary research company that develops and
acquires products in the fields of molecular medicine, electro-optics,
biological handling and natural and formulary compounds. Vivakor also
provides contract research services for third parties.

Vivakor's business model is to be a research hub focused on areas that have
both an identified scientific need and a substantial market opportunity with a
significant market. This approach is intended to provide the necessary
environment of transdisciplinary collaboration and cross-pollination to
advance research and technology acquisition. Vivakor's mission is to advance
or acquire distinct intellectual property and technologies that improve the
quality of life for individual patients, researchers, clinicians and
consumers. Vivakor believes that the development and commercialization of
substantive technologies and cures for complex human conditions, illnesses and
diseases require a sophisticated approach with contribution from many areas of
business and scientific expertise. Vivakor's research and the technology it
acquires are anchored by its relationship with collaborative partners and
product-specific commercialization strategies. From the commencement of
product conception or acquisition, through development and commercialization,
the Company expects to have collaborative partners or licensing arrangements
in place for each of its products. Vivakor expects this model to provide
several advantages, including: (i) a more efficient research and development
process; (ii) a quicker time to market after completion of development; and
(iii) the value-add growth to the hub company, Vivakor, through
commercialization and subsidiary spin-off.

Vivakor has commenced developing numerous products and currently has one
pending utility patent. In October, 2008, it acquired a patented MRI software
technology that it intends to develop. Vivakor generally intends to
commercialize its products, after completion of development and any required
regulatory approvals, primarily through one of three methods: (i) a sale of
the technology; (ii) licensing of the product to a manufacturer or distributor
or; (iii) by directly manufacturing, marketing and selling the products.

Product Research Divisions
Vivakor's research efforts are divided into four primary areas of medical and
biotechnological development. These are:

1. Molecular Medicine. The goal of this division centers on the development
of biologically relevant molecules, tests and methods and their application in
the practice of medicine.

Vivakor plans to translate systems biology (genomics, proteomics,
metabalomics, etc.) insights of the molecular and cellular basis of disease
into commercializable theranostic (diagnostic/therapeutic) products. Vivakor
scientists will be participants in the discovery and development of new drugs
and the early diagnosis of disease states.

The central aim of the molecular medicine division is cancer detection and
wound healing, which we anticipate will lead to the development of customized
treatments. Research in stem cell biology and nuclear reprogramming is a
critical element in this research.

2. Electro-Optics. This division is charged with the development of
biomedical and related consumer products that incorporate optical and
electronic engineering. Vivakor has actively designed, built and tested
several new electro-optic devices to reach previously un-served or underserved
areas of the biomedical device market and believes the market potential during
the first 12 months of commercialization of these products is over $15
million. Products scheduled for development in this area include:

-- VivaSight: a digital photorefractor that is intended to modernize
child
vision screening. Approval has been granted from Western
Institutional
Review Board (20080731) to conduct human validation studies of the
VivaSight technology on children. This study is currently being
conducted at The University of Iowa Hospitals and Clinics.

-- Clinical Biomolecular Sensor (CBS): a label free multiplexed approach
for use in the detection and diagnosis of complex human conditions
(cancer, infectious diseases, cardiovascular disease, metabolic
disorders, auto immune and inflammatory diseases)Multi-spectral
Imaging:
devices to examine burn degree and cutaneous melanoma and

-- Spectroscopic devices: to track wound healing and ear infection.

With the acquisition of HealthAmerica's SLICES(TM) technology, the Company
plans to adapt and upgrade this technology to produce enhanced MRI images,
which are expected to improve MRI resolution while providing additional data
such as blood flow velocity in imaged tissues. The Company believes its
potential market share for this product is over $300 million annually .

3. Biological Handling. Vivakor has developed commercial products for
cryogengenic preservation, and storage through its VivaThermic Cryovials
(USPTO Utility Patent # 12423998) which are currently being sold and have
improved temperature control and were designed to improve cryopreservation and
thawing of sensitive biological material. Vivakor expects that the market
potential for its products is over $10 million over the next 12 months. It
plans to continue to explore new techniques to improve methods and products
employed for cryogenic preservation, storage and handling. Future research
plans for this division include:

-- stem cell specific improved cryovials;
-- cryogenic devices for temperature maintenance and sample transport);
-- a cryogenic biopsy device (Cryopsy); and

-- improved modular cryogenic freezer designs.

4. Natural and Formulary Products. This division plans to focus on the
investigation, validation and adaptation of medical herbalism or botanical
medicine. The Company has already developed a series of nutraceutical
formulations, including VivaBlend, and plan to develop additional
nutraceuticals, botanicals and supplements. Vivakor recently received a
25,000 unit purchase order for one of our products from Regeneca,
International. Future products for this division include:

-- fruit and vegetable extract for the protection of digestive system
-- fresh fruit and vegetable extract for antioxidant supplements; and

-- jam and jelly formula to contain both antioxidant supplements as well
as
bone & cartilage supplements for healthy joints

More information can be found about Vivakor at www.vivakor.com.

About Regeneca International, Inc.
Regeneca(TM) International, Inc. was formed to create and commercialize
products that help consumers improve their health, battle the signs and
symptoms of aging and to assist you "regenerate their life" through its family
of natural, organic and phytochemical infused products. The corporate creed is
to regenerate the human genetic environment through ecology centric science.
All REGENECA(TM) products must fit the highest standard of conservation, and
reduced carbon footprint. The products must also work to preserve and promote
the user's health at the most elemental level of life; the genetic level. The
Company's products and philosophy are designed to reconnect the consumer to
the Earth's source of healing properties, but with a symbiotic approach. This
is the Company's "Whole Earth, Whole Body Approach to Health."

Already a market presence in the multibillion dollar nutraceutical market,
Regeneca's proprietary, direct to consumer; marketing strategy has pushed the
company to the forefront of emerging consumer product companies. Regeneca
anticipates at least a 500% increase in sales in 2010 and a similar increase
in 2011.

More information can be found about Regeneca International, Inc. at
www.regeneca.com .

FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements, including, but not
limited to, statements regarding Vivakor's products and divisions and their
related market potential. There may also be similar statements regarding
Regeneca and its product divisions. Forward-looking statements may be
identified by the use of the words "anticipates," "expects," "intends,"
"plans," "should," "could," "would," "may," "will," "believes," "estimates,"
"potential," or "continue" and variations or similar expressions. These
statements are based upon the current expectations and beliefs of management
and are subject to certain risks and uncertainties that could cause actual
results to differ materially from those described in the forward-looking
statements. These risks and uncertainties include, but are not limited to,
risks and uncertainties discussed in Vivakor's filings with the Securities and
Exchange Commission, which factors are incorporated herein by reference.
Readers are cautioned not to place undue reliance on any of these
forward-looking statements. Vivakor undertakes no obligation to update any of
these forward-looking statements to reflect events or circumstances after the
date of this press release or to reflect actual outcomes.

Contact:
Vivakor, Inc.
Matt Nicosia, 319-625-2172
mnicosia@vivakor.com

SOURCE Vivakor, Inc.

Matt Nicosia, Vivakor, Inc., +1-319-625-2172, mnicosia@vivakor.com